Halberd Corporation (OTCMKTS:HALB) is moving down in the opening after the news.
Market Action
As of 10:32, HALB stock is down by 4% to $0.0250 with more than 606k shares, compared to its average volume of 9.33 million shares. The stock has moved within a range of $0.0250 – 0.0300 after opening the trade at $0.0300.
Major Trigger:
Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process
Key Highlights:
- Halberd Corporation’s (OTC PINK:HALB) proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means. Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to the combined population of the states of Florida and New York.
Halberd has completed Steps 1-3. Step 4 is underway at Youngstown State University (YSU), under the direction of Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Sciences Department. Dr. Sturrus, stated, “The uniqueness of the methodology and approach has presented some equally unique problems. The team is working to overcome and resolve these challenges. We have had to invent measurement techniques; resolve power, frequency and time exposure issues; particle size optimization; etc. Some of these issues persist, but all of them are being addressed.”
Key Quote:
William A. Hartman, Halberd’s Chairman, President & CEO, commented, “As a team, Halberd and its two state university partners along with GreenBioAZ remain 100% focused on developing an effective treatment for Alzheimer’s Disease. Recently we announced the identification of three target antigens to eliminate by our process. After consulting with experts, we have broadened our list of target antigens to include a proprietary list of contributing inflammatory cytokines which increases our probability of success. All of the work Halberd has done to date has laid the foundation for our current program to treat Alzheimer’s disease utilizing our patented and patent-pending technologies.”
 Falls In Opening Trade: What Next?){kind=link}